Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Use Reduces Risk of Early-Onset Colorectal Cancer in Patients with Type 2 Diabetes-Mellitus (T2DM)

被引：0

作者：

Olasehinde, Temitope ^{[1
]}

Cooper, Gregory ^{[1
]}

Perez, Jaime A. ^{[1
]}

机构：

[1] Case Western Reserve Univ, Univ Hosp, Cleveland Med Ctr, Dept Neurol, Cleveland, OH USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期

关键词：

D O I：

10.14309/01.ajg.0001031256.48901.46

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S472

引用

页码：S329 / S330

页数：2

共 50 条

[1] Adherence to Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Therapy in Patients with Type 2 Diabetes Mellitus (T2DM)
Johnston, Stephen
Nguyen, Hiep
Felber, Eugene
Cappell, Katherine
Nelson, James K.
Chu, Bong-Chul
Kalsekar, Iftekhar
DIABETES, 2014, 63 : A604 - A604
[2] Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients
Fazeli, Sasan
Ehrhardt, Nicole
DIABETES, 2018, 67
[3] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
Hiep Nguyen
Robert Dufour
Amanda Caldwell-Tarr
Advances in Therapy, 2017, 34 : 658 - 673
[4] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
Nguyen, Hiep
Dufour, Robert
Caldwell-Tarr, Amanda
ADVANCES IN THERAPY, 2017, 34 (03) : 658 - 673
[5] HEALTH CARE COSTS AMONG TYPE 2 DIABETES MELLITUS PATIENTS INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA) THERAPY
Johnston, S. S.
Nguyen, H.
Felber, E.
Cappell, K.
Nelson, J.
Chu, B. C.
Kalsekar, I
VALUE IN HEALTH, 2014, 17 (03) : A244 - A244
[6] PATIENT PREFERENCES FOR FREQUENCY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA) INJECTIONS IN THE TREATMENT OF TYPE 2 DIABETES
Hauber, A. B.
Nguyen, H.
Posner, J.
Ervin, C. M.
LaRue, S.
Kalsekar, I
VALUE IN HEALTH, 2014, 17 (03) : A255 - A255
[7] Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes
Ng, Elisabeth
Shaw, Jonathan E.
Wood, Anna
Maple-Brown, Louise J.
Hare, Matthew J. L.
AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2022, 51 (07) : 513 - 518
[8] TTP273, an Orally-Available Glucagon-like Peptide-1 (GLP-1) Agonist, Notably Reduces Glycemia in Subjects with Type 2 Diabetes Mellitus (T2DM)
Gustavson, Stephanie
Burstein, Aaron
Valcarce, Carmen
Grimes, Imogene
Mjalli, Adnan
DIABETES, 2014, 63 : A41 - A41
[9] GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA) AND UPPER ENDOSCOPY: A REAL WORLD EXPERIENCE
Siranart, Noppachai
Thompson, Christopher
Jirapinyo, Pichamol
GASTROINTESTINAL ENDOSCOPY, 2024, 99 (06) : AB307 - AB307
[10] Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) plus Basal Insulin vs. GLP-1RA in Type 2 Diabetes Mellitus-A Systematic Review and Meta-analysis
Satti, Muniza M.
O'Brien, Timothy
Liew, Aaron
DIABETES, 2018, 67

← 1 2 3 4 5 →